drugset / Trial / NCT07265206
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Timeline
- Start
- 2025-12-30
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HY001N | Cell therapy | — | — |